The seven marketing authorization applications (MAAs) that are up for an opinion this week on whether they should be marketed in the EU include two vaccines from Sanofi – one for the prevention of invasive meningococcal disease, including meningitis, and one for flu.
Also up for an opinion is a generic version of rivaroxaban. This appears to be the first generic version of...








